Loading clinical trials...
Loading clinical trials...
This is a Phase 2, open-label, randomized, multicenter study to assess the efficacy and safety of DZD8586 in patients with primary immune thrombocytopenia (ITP). The target population of this study is...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Dizal Pharmaceuticals
NCT07175493 · Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), and more
NCT06888960 · Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), and more
NCT07095127 · Immune Thrombocytopenia (ITP)
NCT06371417 · Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), and more
NCT06853444 · Immune Thrombocytopenia (ITP)
Qilu Hospital of Shandong University
Jinan, Shandong
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions